Nifev Capsule 150 mg contains Nintedanib, a targeted medication used in the management of certain chronic and progressive lung conditions. It is formulated to slow disease progression by inhibiting key pathways involved in abnormal tissue remodeling and fibrosis. This capsule strength—150 mg—is commonly prescribed for adult patients requiring therapeutic dosing to maintain lung function and delay worsening symptoms.

Nintedanib belongs to a class of medicines known as tyrosine kinase inhibitors. These agents work by blocking multiple receptors, including those for platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF). By inhibiting these pathways, Nintedanib helps reduce the signaling that drives fibrosis (the buildup of scar-like tissue) in the lungs. The result is a slower decline in lung function and stabilization of the disease process.

Nifev Capsule 150 mg is indicated in adults for conditions such as:

• Idiopathic Pulmonary Fibrosis (IPF): A chronic, progressive lung disease of unknown cause characterized by irreversible scarring.

• Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype: These are a group of similar fibrosing lung disorders where scarring progresses over time.

• Other Fibrotic Lung Conditions: Based on clinical judgment and regulatory approvals, Nintedanib may be prescribed for additional fibrosing diseases that show progressive decline.

Regular monitoring by a healthcare provider is essential during treatment with Nifev Capsule 150 mg. Before initiating therapy, baseline liver function tests are recommended because Nintedanib undergoes hepatic metabolism and may impact liver enzyme levels. Periodic testing throughout treatment helps ensure safety, detect possible adverse effects early, and guide dose adjustments if needed.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Features

• Active Ingredient – Nintedanib: A potent tyrosine kinase inhibitor that targets multiple growth factor receptors contributing to fibrosis.
• Strength – 150 mg: Standard adult therapeutic dose aimed at optimal disease control.
• Indicated for Progressive Lung Diseases: Especially suited for idiopathic pulmonary fibrosis and other fibrosing interstitial lung disease subtypes showing progression.
• Action Mechanism: Slows lung scarring and functional decline by interrupting pathways responsible for abnormal tissue formation.
• Oral Administration: Easy-to-take capsule format improves compliance for long-term therapy.
• Monitoring Guidance: Liver function tests and regular follow-up evaluations are part of safe treatment.

How Nifev Capsule 150 mg Works

When lung tissue becomes damaged, the body’s healing response can overreact, causing excessive collagen deposition and scarring. Over time, this fibrosis makes the lungs stiffer and less efficient at gas exchange, leading to shortness of breath and reduced quality of life.

Nintedanib disrupts this process by binding to tyrosine kinase receptors involved in cell proliferation, angiogenesis, and fibrogenesis. By inhibiting these receptors, it reduces the signaling that drives fibroblast activation and scar tissue formation. This action helps slow the progression of fibrotic changes in the lungs, preserving respiratory capacity for a longer duration.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Usage Guidelines

• Take exactly as prescribed by your healthcare provider.

• Swallow the capsule whole; do not crush or open.

• Usually taken twice daily with food to improve tolerability.

• Stay hydrated and report any unusual symptoms promptly.

• Inform your doctor of all other medications and supplements to prevent interactions.

Safety and Precautions

While Nifev Capsule 150 mg can offer meaningful benefit, some patients may experience side effects such as diarrhea, nausea, liver enzyme elevations, or reduced appetite. Dose modification or supportive care may be recommended to manage these effects. Discuss any concerns with your physician to optimize therapy and minimize risks.